Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 8,270 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions: aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more

Conditions: Trauma Injury, Trauma, Open Fracture, Fracture Infection
Interventions: Open Fracture, Infected Fracture; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Alcohol Abuse
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Fibula Fracture
Interventions: Fibulock; Device
Lead sponsor: Arthrex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Miami, Florida • Durham, North Carolina • Westerville, Ohio

Conditions: Dermatitis Atopic
Interventions: Dupilumab SAR231893; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Denver, Colorado

Conditions: HIV (Human Immunodeficiency Virus)
Interventions: Conventional Smell Training Group, Scented Marker Group; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cervical Radiculopathy
Interventions: Injection with Gadolinium; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome, Fragile X Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Mental Retardation, X-Linked, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Trisomy 13 Syndrome, WAGR Syndrome, Williams Syndrome
Interventions: PACE Program; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Chapel Hill, North Carolina

Conditions: Advanced Age-related Macular Degeneration
Interventions: LFG316; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more

Conditions: Cancer, Predictive Cancer Model, Effects of Chemotherapy
Interventions: Known 3Dx Test; Diagnostic Test
Lead sponsor: Known Medicine, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Rochester, Minnesota • Durham, North Carolina • Houston, Texas

Conditions: Pollution; Exposure, Smoke Inhalation, Exposure to Pollution
Interventions: Cigarette Smoke, Clean Air and Clean Clothing/Sham exposure; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions: Bio-specimen Collection: Blood, Bio-specimen Collection: Pancreatic Juice, MRI; Other · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Age-Related Macular Degeneration
Interventions: Palomid 529; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19
Interventions: Assessing the impact of COVID-19; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Timeline: 2020
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Choroidal Neovascularization, Wet Macular Degeneration
Interventions: ICON-1, aflibercept; Biological
Lead sponsor: Iconic Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more

Conditions: Age Related Macular Degeneration (AMD)
Interventions: GT005; Genetic
Lead sponsor: Gyroscope Therapeutics Limited; Industry
Eligibility: 55 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 22
States / cities: Poway, California • Durango, Colorado • Gainesville, Florida + 18 more

Conditions: Bronchiolitis
Interventions: Dexamethasone Oral; Drug
Lead sponsor: IDeA States Pediatric Clinical Trials Network; Network
Eligibility: 0 Months to 24 Months
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Little Rock, Arkansas • Omaha, Nebraska

Conditions: Chronic Obstructive Pulmonary Disease, Aging
Interventions: Fiber Inulin, Placebo Maltodextrin; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Interventions: Not listed
Lead sponsor: Complement Therapeutics; Industry
Eligibility: 65 Years and older
Enrollment: 234 participants
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Glendale, California • Mountain View, California • Carmel, Indiana + 7 more

Conditions: Stress Urinary Incontinence in Women
Interventions: Daily Disposable Continence Device, Monthly Disposable Continence Device; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Knee Osteoarthritis
Interventions: High Frequency TENS, Low frequency TENS, Placebo TENS; Procedure
Lead sponsor: University of Iowa; Other
Eligibility: 30 Years to 95 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy
Interventions: ENGN Shred, Nutricost caffeine powder, Crystal Light; Dietary Supplement
Lead sponsor: Northern Illinois University; Other
Eligibility: 19 Years to 29 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: DeKalb, Illinois

Conditions: HIV, Pediatric
Interventions: Atazanavir, Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: Phoenix, Arizona • Atlanta, Georgia • Dallas, Texas

Conditions: Cardiac Fibrosis, Diastolic Dysfunction
Interventions: Pycnogenol, Placebo; Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 50 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

OCT in Open Fracture and Infected Fracture

Brain-imaging and Adolescent Neuroscience Consortium

Effectiveness Of The Fibulock Intramedullary Nail

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

Boosting Olfactory and Sensory Training Study (BOOST)

Dispersal Pattern for Spine Injections (Gadolinium Contrast)

Physical Activity and Community EmPOWERment Project

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models

Controlled Exposure of Healthy Nonsmokers to Secondhand and Thirdhand Cigarette Smoke

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration

Impact of COVID-19 on Marshallese Communities in the U.S.

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

The Bronchiolitis in Hospitalized Infants Study

Fiber Metabolism in Chronic Obstructive Pulmonary Disease

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

Comparison of Two Over the Counter Intravaginal Devices for the Treatment of Stress Urinary Incontinence

TENS Effectiveness and Knee Osteoarthritis in Humans

Pre-workout Supplement Versus Caffeine on Energy Expenditure.

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects